#aduhelm

[ follow ]
Ars Technica
3 months ago
OMG science

Biogen dumps dubious Alzheimer's drug after profit-killing FDA scandal

Biogen is abandoning its Alzheimer's drug Aduhelm and terminating all development and commercialization activities.
The drug failed two Phase 3 trials and has faced controversy over its regulatory approval and pricing. [ more ]
www.nytimes.com
3 months ago
Medicine

Biogen Abandons Its Controversial Alzheimer's Drug Aduhelm

Biogen is abandoning its ownership rights to the Alzheimer's drug Aduhelm, after it failed to gain traction in the market.
The decision to abandon Aduhelm comes after the drug faced criticism for its weak evidence of efficacy, high price, and safety risks. [ more ]
[ Load more ]